CYTENA Launches C.STATION, a Fully Automated Platform for Stable Cell Line Development to Streamline Production of Antibody and Gene Therapies

Today CYTENA, a BICO company, launched C.STATION, a new platform for fully automated stable cell line development. The platform combines CYTENA’s already proven single cell dispensing technology along with its best-in-class liquid handling expertise to enable affordable and high-quality laboratory automation. This combination of technologies advances BICO’s Bio Convergence agenda and democratizes access to production of next generation healthcare solutions including antibody therapies, gene therapies, and biosimilar production.

“C.STATION is a key step in advancing the Bio Convergence revolution by combining several proven technologies, cell cultures, and smart software to produce monoclonal antibodies and viral vectors for gene therapy,” explained Dr. Julian Riba, CEO of CYTENA. “I could not be more proud of our team for their work on this incredible platform and am excited to bring this to our already hundreds of existing customers working on cell line development.”

The C.STATION covers the entire cell line development workflow from single-cell cloning of transfected cells to selecting high-producing clones and upscaling. By integrating proven technologies and protocols into a user-friendly platform, the C.STATION will democratize laboratory automation in this important healthcare field. Using the platform, thousands of clones can be isolated, screened, and selected for upscaling with minimal user interaction. Since the work cell relies on standard well plates it can be readily integrated into existing lab infrastructure.

Along with cell line development, CYTENA develops award-winning products across liquid handling, single cell dispensing, bioreactors, live cell analysis, and NGS reagents. Its devices are used in labs by leading life science organizations that include AstraZeneca, Bayer, Genentech, Sanofi, Novo Nordisk, GlaxoSmithKline, Novartis, the National Institutes of Health, Merck, Bristol-Myers Squibb, Amgen, and others.